Indication
Maroteaux-Lamy syndrome
Maroteaux-Lamy syndrome, also known as mucopolysaccharidosis type VI (MPS VI), is a rare autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme arylsulfatase B (N-acetylgalactosamine-4-sulfatase). Read more about Maroteaux-Lamy syndrome
1 drugs 1 manufacturers
Drugs that treat it
Common Maroteaux-Lamy syndrome therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMaroteaux-Lamy syndrome, also known as mucopolysaccharidosis type VI (MPS VI), is a rare autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme arylsulfatase B (N-acetylgalactosamine-4-sulfatase).
This enzymatic defect prevents the normal degradation of the glycosaminoglycan dermatan sulfate, leading to progressive intracellular accumulation and widespread tissue and organ dysfunction primarily beginning in childhood.
The multisystem clinical presentation is characterized by dysostosis multiplex, short stature, joint stiffness, coarse facial features, corneal clouding, hepatosplenomegaly, and cardiopulmonary complications such as heart valve disease and upper airway obstruction, typically without affecting cognitive development.
- rarediseases.org
Maroteaux-Lamy syndrome, also known as mucopolysaccharidosis type VI (MPS VI), is a rare autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme arylsulfatase B (N-acetylgalactosamine-4-sulfatase) This enzymatic defect prevents the normal degradation of the glycosaminoglycan dermatan sulfate, leading to progressive intracellular accumulation and widespread tissue and organ dysfunction primarily beginning in childhood The multisystem clinical presentation is characteriz...
- nih.gov
Maroteaux-Lamy syndrome, also known as mucopolysaccharidosis type VI (MPS VI), is a rare autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme arylsulfatase B (N-acetylgalactosamine-4-sulfatase)
- medlineplus.gov
This enzymatic defect prevents the normal degradation of the glycosaminoglycan dermatan sulfate, leading to progressive intracellular accumulation and widespread tissue and organ dysfunction primarily beginning in childhood The multisystem clinical presentation is characterized by dysostosis multiplex, short stature, joint stiffness, coarse facial features, corneal clouding, hepatosplenomegaly, and cardiopulmonary complications such as heart valve disease and upper airway obstruction, typically ...
Personalize your experience
Follow Maroteaux-Lamy syndrome and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.